Impact of the interaction between the polymorphisms and hypermethylation of the CD36 gene on a new biomarker of type 2 diabetes mellitus: circulating soluble CD36 (sCD36) in Senegalese females

Maïmouna Touré1,5*, Abdoulaye Samb1,5, Mbaye Sène2, Souleymane Thiam3, Cheikh A. B. Mané1, Abdou K. Sow1, Awa Ba-Diop4, Modou O. Kane2, Mamadou Sarr2, Abdoulaye Ba1,5 and Lamine Gueye1,5

Abstract

Background: Several predisposing factors for diabetes mellitus have been identified, including cluster determinant 36 (CD36) receptor expression. We aimed to determine the effects of CD36 gene polymorphisms and hypermethylation on the plasma CD36 protein levels in type 2 diabetes.

Materials and methods: We conducted a cross-sectional study involving 100 females (lean healthy control subjects and subjects with type 2 diabetes). This study was conducted at the Human Physiology Laboratory at the Dakar Faculty of Medicine in Senegal. Circulating sCD36 levels and DNA methyltransferase 3a levels were determined by enzyme-linked immunosorbent assay. The other biological parameters were evaluated in a biochemical laboratory. CD36 gene polymorphisms and methylation were explored by real-time polymerase chain reaction and methylation-specific polymerase chain reaction, respectively.

Results: sCD36 was negatively correlated with HDL-cholesterol levels ($r = -0.52 \ p = 0.0001$) and triglyceride levels ($r = -0.36 \ p = 0.01$) in control subjects. However, in the type 2 diabetes group, sCD36 levels were positively correlated with total cholesterol levels ($r = 0.28 \ p = 0.04$). For rs3211867, control subjects harboring the CC genotypes had significantly higher sCD36 levels than control subjects harboring the AA/AC genotype ($p = 0.02$); in the type 2 diabetes group, the sCD36 level was not significantly lower in subjects harboring the AA/AC genotype than in subjects harboring the CC genotype ($p = 0.27$). CD36 gene methylation reduced the sCD36 level in the control subjects compared to control subjects without CD36 gene methylation ($p = 0.03$). This difference was not significant in the type 2 diabetes group comparing subjects with diabetes with CD36 gene methylation to subjects with diabetes without CD36 gene methylation ($p = 0.09$). We noted a nonsignificant increase in sCD36 levels in subjects with diabetes with CD36 gene...
methylation compared to control subjects with CD36 gene methylation ($p=0.27$). A combination of the CD36 polymorphism effect and the CD36 methylation effect did not significantly reduce sCD36 levels in subjects with type 2 diabetes.

**Conclusion:** CD36 gene polymorphisms and CD36 gene methylation separately reduce sCD36 levels. Their impacts are compensated for in subjects with type 2 diabetes by an increase in sCD36 levels, the mechanism of which needs to be elucidated.

**Keywords:** sCD36 protein, Genetic polymorphism, DNA methylation, Type 2 diabetes

### Introduction

Diabetes mellitus is a metabolic disorder that is among the top 10 causes of death in adults, and its incidence is 1.6 times higher in females than in men [1]. From the public health perspective, the identification and evaluation of new biomarkers that could be useful in diagnosing and monitoring type 2 diabetes mellitus (T2DM) before clinical manifestations have been challenging. Thus, it is important to identify biomarkers linked to diabetes mellitus that can be used to further understand its pathophysiology.

Cluster determinant 36 (CD36) is a multifunctional signaling molecule with several known ligands, including long-chain fatty acids and both native and atherogenic lipoproteins as oxidized low-density and high-density lipoproteins [2]. The CD36 gene has been strongly implicated in pathological conditions associated with metabolic dysregulation, such as insulin resistance [3, 4] and type 2 diabetes [5, 6]. Recently, a circulating plasma form of CD36 protein termed soluble CD36 (sCD36) was identified [7, 8]; it is an indirect reflection of CD36 expression in tissues [9]. Previous studies have indicated that sCD36 is strongly correlated with insulin resistance and the development of type 2 diabetes [7, 8, 10, 11]. Thus, sCD36 is considered a novel biomarker for type 2 diabetes mellitus [7]. Therefore, the expression of CD36 and its reflection sCD36 could be considered an important pillar of this disease. Furthermore, it could explain a large part of the underlying pathophysiology of type 2 diabetes, especially in obese subjects.

Since type 2 diabetes is a heterogeneous disease whose onset and progression depend on genetic and environmental factors, epigenetic mechanisms may also play a key role in the pathology of diabetes and its complications. The evaluation of the effects of genetic and epigenetic variability on the expression of the CD36 gene and therefore on sCD36 during type 2 diabetes seems interesting. Studies in different populations have reported that several CD36 variants, including rs1761667 and rs3211867, are associated with changes in CD36 expression that have consequent abnormalities in fasting glucose and lipid metabolism [12–14]. To the best of our knowledge, there is no research on the associations between sCD36 and CD36 SNPs and gene methylation in a Senegalese population. Therefore, the objective of this study was to assess the role of sCD36 in type 2 diabetes and the influence of two common CD36 intronic SNPs, rs1761667 (G/A) and rs3211867 (C/A), and CD36 gene methylation in Senegalese females.

### Patients and methods

#### Patients

This study was conducted at the human physiology laboratory at the Dakar faculty of medicine in Senegal. We enrolled the study population subjects by random sampling. A total of 100 Senegalese females were enrolled in this cross-sectional study (50 healthy control subjects and 50 subjects with type 2 diabetes). The inclusion criteria were an age of 18 years or older for all groups, and subjects were matched according to age. These subjects voluntarily agreed to participate in the study and were selected during the same time period.

For the control subjects, we included females in good health, confirmed by clinical and biological examinations. They were neither pregnant nor breastfeeding. In the survey on the family history of the control subjects, we found that 3 control subjects had at least one family member with a lipid disorder, 6 control subjects had at least one obese family member, and 2 control subjects had at least one family member with type 2 diabetes. The subjects were excluded from the study. This family survey focused only on first-degree relatives (father, mother, brothers, and sisters) (Additional file 1).

Additionally, we recruited females who were confirmed to have type 2 diabetes and were followed at the national diabetology center of Senegal for their medical follow-up. In this study, type 2 diabetes mellitus was confirmed by clinical and biological examinations (fasting blood glucose and glycosylated hemoglobin levels) according to the World Health Organization (WHO) diabetes diagnostic criteria set in 1979. The exclusion criteria for subjects with diabetes were as follows: pregnant or breastfeeding females and those with other pathological conditions, such as type 1 diabetes mellitus, systemic diseases, inflammatory chronic diseases, autoimmune
diseases, tumors, thyroid dysfunction (current hypo- or hyperthyroidism), and liver and kidney diseases (Additional file 2).

The study protocol was carried out according to the Declaration of Helsinki (1989) of the World Medical Association and was approved by our institutional ethics committee of UCAD (Protocole 027512018/CERruCAD). Our experimental protocol conforms to the relevant ethical guidelines for human research. Informed written or oral consent was obtained from all the participants.

**Clinical procedures**

At recruitment, all the subjects underwent an interview using a pre-established questionnaire that included demographic characteristics (age, sex, and education level), medical histories (diabetes mellitus and other diseases), and lifestyle habits (smoking, drinking, sports, etc.). The interview was followed by a clinical examination.

Clinical examination and anthropometric measures (weight, height, waist circumference, hip circumference, waist-to-hip ratio, body mass index, and blood pressure) were performed on each subject (Additional files 1 and 2).

**Laboratory biological measurements**

Blood samples were obtained the same day in the biochemistry laboratory in the FMPOS of UCAD. Samples were obtained before the interviews after a 12-h overnight fast. Fasting venous blood was collected from all participants at the fold of the elbow of the nondominant arm. For each patient, the collected blood was distributed in a fluoride tube for the determination of fasting blood glucose levels, in a heparin tube for the measurement of lipid levels (total cholesterol, high-density lipoprotein cholesterol (HDLC-cholesterol), low-density lipoprotein cholesterol (LDL-cholesterol), and triglycerides) and the renal function evaluation (uremia and creatininemia), and in a tripotassium ethylenediaminetetraacetate acid tube (EDTA K3) for the determination of glycated hemoglobin and DNA extraction. Blood, serum, and plasma were aliquoted and frozen at −80 °C for further analysis.

Serum glucose concentrations were measured by the glucose oxidase method. Glycosylated hemoglobin was measured by high-performance liquid chromatography. Total serum cholesterol was measured through the reaction of cholesterol esterase/cholesterol oxidase/peroxidase, and total serum triglycerides were measured through the reaction of glycerol-phosphate-oxidase and peroxidase. The LDL-cholesterol concentration was calculated using the following formula: LDL-cholesterol = total cholesterol – HDL-cholesterol – triglycerides/5 [15].

Plasma insulin levels were determined by an enzyme-linked immunosorbent assay (insulin (human) ELISA Kit #A05322.96 wells, version 0118, Bertin bioreagent, France) (Additional file 5).

Insulin resistance was determined by the Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) using the following Matthews formula: HOMA-IR = (insulin (mUI/L) × glucose (mmol/L)) / 22.5 [16].

Plasma concentrations of human sCD36 were measured using a commercially available CD36 (human) enzyme-linked immunosorbent assay (ELISA) kit (CD36 (human) ELISA kit #KA4204, version 09, abnova, France) (Additional file 6).

Serum DNMT3a levels were measured by using commercially available Human DNMT3a ELISA kits (human DNA (cytosine-5)-methyltransferase 3a, Kit KTE62548, Abbkine, Wuhan, China). In this study, we used the dosage of the enzyme DNMT3a to support the observed methylation of the CD36 gene (Additional file 4).

**Genotyping and methylation analysis**

Blood samples for DNA extraction were collected in EDTA K3 tubes. Genomic DNA (gDNA) was extracted from venous peripheral blood leukocytes using the commercially available Spin-column technique kit for DNA extraction from human whole blood (The PureLink™ Genomic DNA purification mini kit, Invitrogen™ by Life Technologies, CA K1820-02, lot 1,977,075, Carlsbad, CA 92008, USA). DNA integrity and concentration were determined by spectrophotometry and electrophoresis. Then, the extracted DNA samples were stored at −20 °C for future use.

**Determination of CD36 gene polymorphisms**

The SNP selection for genotyping was conducted following certain conditions. Table 1 shows some of the characteristics of the studied SNPs. To cover a good part of the CD36 genetic variability in the study, we included 2 tag SNPs (rs3211867 and rs1761667). The criteria used in our SNP selection procedure were as follows: (1) minor allele frequency (MAF) > 0.05; (2) 1 tag SNP block among the 5 large SNP blocks in the HapMap database of 2008: rs3211867 is from block 4 (tagging 8 other SNPs); and (3) 1 tag SNP (rs1761667), which was not present in the study.

| CD36 variant | Alleles | RefSNP ID | Location |
|--------------|---------|-----------|----------|
| −31,118      | G > A   | rs1761667 | exon 1A  |
| 11,472       | C > A   | rs3211867 | intron 3 |
HapMap database of 2008 but was chosen based on data from the literature.

The two tag SNPs were detected using standard assays on demand C_8314999_10 and C_1803793_10.

Determination of CD36 gene polymorphisms was carried out with TaqMan® SNP Genotyping Assays (TaqPath™ ProAmp™ Master Mixes, ThermoFisher Scientific, MA, USA) by the real-time polymerase chain reaction (RT–PCR) System and allele discrimination technique (TaqMan, Applied Biosystems, Assay Catalog Number 4351379 Foster City, CA, USA) on a 96-well format and read by a StepOne Plus thermocycler (Applied Biosystems, Foster City, CA, USA). The PCR mixture was composed of prepared DNA with distilled water (20 ng in 4.5 µL), 2X TaqMan® Master Mix (5 µL), and working Stock 0X Assay (0.5 µL) to reach a total volume of 10 µL. After an initial step (Pre-PCR Read: Holding Stage) of 30 s at 60 °C and 1 min at 95 °C to activate the AmpliTaq Gold, UP, and enzyme activation, the products were amplified (cycling stage) using 40 cycles of 15 s at 95 °C and 1 min 30 s at 60 °C. Next, the post-PCR read (holding stage) was performed for 30 s at 60 °C. Then, allele detection and genotyping calling were performed using StepOne plus (Corbett Research, Mortlake, New South Wales, Australia) with the available installed software. The amplification parameters were as follows: 95 °C for 2 min; 94 °C for 30 s, 60 °C for 1 min, 72 °C 1 min for 35 cycles, 72 °C for 10 min, and then held at 4 °C until storage using TaqMan SNP assays (Applied Biosystems).

**Determination of CD36 gene methylation**

Sodium bisulfite modification Genomic DNA was modified with sodium bisulfite using the CpGenome Direct Prep Bisulfite Modification Kit (Catalog No. 17–10,451, Merck KGA, Darmstadt, Allemagne). Briefly, 500 ng of DNA diluted with RNase-free water (12 µl) was mixed with 13 µl of 2 × extraction buffer and 1 µl of proteinase k, up to 26 µl. The conversion of the bisulfite DNA was carried out in a thermocycler under the following conditions: 8 min at 98 °C, 3 h 30 min at 64 °C, and hold at 4 °C. After conversion and purification, modified DNA was stored at −20 °C.

Methylation-specific PCR (MS-PCR) For the methylation analysis, we selected CpG located at −293.337 (promoter region) of CD36. Primers for both sequences were designed with MethPrimer. DNA was amplified with two pairs of primers, one for the methylated template and the other for the unmethylated sequence, and the PCR products were 103 bp. Primers for the methylated and unmethylated sequences produced products the same length as the PCR products (Fig. 1) [17] (Additional file 3).

For the PCR assay, 2 µL of bisulfite-modified DNA was amplified in a total volume of 25 µL containing the following: 12.5 µL PCR master mix (Maitre PCR Gotaq® long 2x, Thermo Scientific Inc., USA), 1 µL of each sense

---

**CD36: 80662315 Chromosome 7 (80, 633,969-80, 671,235) CpG Island Sequence: 293 340 downstream (80662000 promoter region)**

| Primer Set | Primer Location | Sequence |
|------------|----------------|----------|
| +315       | M-forward      | GGGACACCGGGGTCTTACACCTCCTG GAGATGCTGTACGTGACCGCTTGTGAGCTGTGGCCCA |
| +375       | M-reverse      | GCATTTCTGCAGCACTATTGTCAGGTCACTGCGAGAGGCTGTGGCCATGAGGTGCTGTGGG |
| +435       | U-forward      | AAGCACGCGGTGTGATGACACCGCTTGCAACAAATGTGCTGCGGACCTTTCTGCACGTTGG |
| +495       | U-reverse      | GCTCCAGCGCTTTGGGACACGCTTATGGCTTGTGCTGGGAATCAT |
| +555       | TA-forward      | GTGCTGAATGTGCACAGATTGTACATAGGATACATGCGATGCTTGTGCTGACCT |
| +615       | TA-reverse     | ATCAAAACCATCATCTAGGTTTTTAAAGCCCGTATGCGCTTAATGCATTAGATAATTGGAGAAG |

**Primer Sets**

- **M-forward (5→3)**: TTAGTTATTTGTTAGAGGTTTCGT
- **M-reverse (5→3)**: AAACACACGTAACAAAAAATAACG
- **U-forward (5→3)**: TGGTTAAGTTATTGTAAGAGGTTTT
- **U-reverse (5→3)**: CCACACATACAAAAAAATACACA

**Fig. 1** Selection of CpG islands and primer design for methylation-specific PCR (MS-PCR). Human CD36 CpG island sequences (promoter region).

Binding sites for transcription factors are underlined. Primer sequences were used for methylation-specific PCR (MS-PCR). Amplified sequences: M-forward primer: primer designed for methylated DNA. U-forward primer: forward primer designed for unmethylated DNA.
and antisense primers, and 8.5 µL of nuclease-free water. For the control, we used human methylated (positive control) and unmethylated (negative control) DNA supplied by the supplier (EpiTect PCR Control DNA Set, Qiagen, USA). For the positive controls, the pretreated DNA showed that the CpG was methylated, and in the same way, in negative control samples, all CpGs were unmethylated. The PCR conditions were as follows: initial denaturation at 95 °C for 4 min; denaturation-extension for 40 cycles at 95 °C for 1 min, 57 °C for 1 min, and 72 °C for 1 min; and a final extension step at 72 °C for 10 min. Amplification was performed in a thermal cycler (iCycler C1000, Bio-Rad, Germany). Finally, 8 µL of PCR product was electrophoresed on a 1% (w/v) agarose gel containing ethidium bromide. The gels were visualized by ultraviolet light (Gel Doc imaging 2000, Bio-Rad).

Statistical analysis
All variables were saved in an Excel table. Quantitative variables were described using the mean ± standard deviation (SD), and qualitative variables were described using absolute values and percentages. Pairwise comparisons of the study parameters between the control subjects and the patients with type 2 diabetes were evaluated by the unpaired Student’s t test. The chi² test was used to evaluate the association between qualitative variables. The correlation test Pearson was used to assess the associations between sCD36 and the other quantitative variables.

The results were considered significant when \( p \leq 0.05 \). The data exploitation was carried out by SPSS software version 23.0 (IBM Company, Mexico, Mexico).

Results
General and biochemical characteristics
The results of the general and biochemical parameters of the participants according to the different groups are shown in Table 2. We found statistically significant anthropometric and metabolic differences between control subjects and subjects with type 2 diabetes (Table 2).

Comparison of the circulating sCD36 protein level according to the groups
In Fig. 2, the sCD36 protein level was not significantly different between the control and type 2 diabetes groups.

Associations between sCD36 and the other study parameters
Table 3 shows the relationship between sCD36 and the anthropometric, glucidic, and lipidic parameters. sCD36 was negatively correlated with HDL cholesterol \( (r = -0.52, p = 0.0001) \) and triglycerides \( (r = -0.36, p = 0.01) \) in control subjects. On the other hand, in the type 2 diabetes group, sCD36 was positively correlated with total cholesterol \( (r = 0.28, p = 0.04) \).

Allelic frequencies and genotypic distribution
Table 4 shows the allelic frequencies and genotype distribution of two CD36 polymorphisms in control subjects and subjects with type 2 diabetes. The two SNPs were consistent with Hardy–Weinberg equilibrium in each group. We found that the allelic frequencies and genotypic distribution of the CD36 gene were not significantly different between the two groups (control and type 2 diabetes).
Table 3 Associations between sCD36 levels and a variety of clinical and biochemical parameters

| sCD36 (pg/ml) | Control n = 50 | Type 2 diabetes mellitus n = 50 |
|--------------|---------------|---------------------------------|
| Body mass index (kg/m²) | r = −0.20 | p = 0.15 | r = 0.06 | p = 0.67 |
| Waist–hip ratio | r = 0.22 | p = 0.12 | r = 0.13 | p = 0.35 |
| Glycated hemoglobin (%) | r = −0.20 | p = 0.16 | r = 0.13 | p = 0.36 |
| HOMA-IR | r = −0.05 | p = 0.74 | r = −0.14 | p = 0.35 |
| Total cholesterol (g/l) | r = −0.24 | p = 0.09 | r = 0.28 | p = 0.04* |
| HDL cholesterol (g/l) | r = −0.52 | p < 0.0001* | r = −0.07 | p = 0.64 |
| LDL cholesterol (g/l) | r = 0.14 | p = 0.34 | r = 0.24 | p = 0.09 |
| Triglycerides (g/l) | r = −0.36 | p = 0.01** | r = 0.09 | p = 0.54 |

HOMA-IR Homeostasis Model Assessment-Insulin Resistance, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.0001

Table 4 Association between CD36 genotypes and the risk of type 2 diabetes mellitus

| SNP CD36 | Control n = 50 | T2DM n = 50 | Statistical calculations Chi²; OR; RR; 95% CI |
|----------|---------------|-------------|------------------------------------------|
| rs1761667 |               |             |                                          |
| HWEX²   | 0.33 (p = 0.57) | 0.02 (p = 0.88) | p = 0.74 |
| VA      | 0.32 | 0.29 |              |
| Genotyping (%) | G | 24 (48%) | 25 (50%) | Chi² = 0.04, p = 0.9 |
| A       | 26 (52%) | 25 (50%) |          |
| Allele (%) | CC | 19 (38%) | 20 (40%) | OR = 0.79 [0.43–1.44] |
| A       | 31 (62%) | 30 (60%) |          |
| rs3211867 |             |             |                                          |
| HWEX²   | 0.83 (0.36) | 0.09 (p = 0.77) | p = 0.39 |
| VA      | 0.36 | 0.36 |              |
| Genotyping (%) | CC | 19 (38%) | 20 (40%) | Chi² = 0.04, p = 0.9 |
| A       | 31 (62%) | 30 (60%) |          |
| Allele (%) | AA/AC | 35 (35%) | 36 (36%) | OR = 1 [0.56–1.79] |
| A       | 65 (65%) | 64 (64%) | OR = 1, RR = 1, 95% CI |

HWEX² Hardy–Weinberg Equilibrium, VA Variation Allelic, OR Odds Ratio, RR Relative risk, T2DM Type 2 Diabetes Mellitus

The study of the genotypic distribution in each group showed that harboring the heterozygous or homozygous genotype of the SNPs considered (rs1761667 or rs3211867) did not lead to a significant difference in the variation in the mean rates of the clinical and biochemical parameters studied (Table 5).

Table 5 divides the entire study population into two groups: a group of subjects harboring the reference homozygous genotype and a group of subjects harboring the heterozygous genotype or the variant homozygous genotype.

For rs1761667, the reference homozygous genotype was the GG genotype, and the heterozygous genotype or variant homozygous genotype was the AA/AG genotype. For the rs1761667 SNP, we found that subjects with diabetes harboring the homozygous reference GG genotype had a higher waist-to-hip ratio than control subjects harboring the homozygous reference GG genotype (p = 0.02). For the same SNP, rs1761667, subjects with diabetes harboring the AA/AG genotype always had a higher waist-to-hip ratio (p = 0.008) and a higher LDL cholesterol level (p = 0.02) than control subjects harboring the AA/AG genotype.

For rs3211867, the reference homozygous genotype was the CC genotype, and the heterozygous genotype or variant homozygous genotype was the AA/AC genotype. For this SNP, we found that subjects with diabetes harboring the homozygous reference CC genotype had a higher waist-to-hip ratio (p < 0.0001) than control subjects harboring the homozygous reference CC genotype. For the same SNP, 3,211,867, subjects with diabetes harboring the variant AA/AC genotype had a higher LDL cholesterol level than control subjects harboring the variant AA/AC genotype (p = 0.02).

sCD36 levels and CD36 gene polymorphisms

We found a statistically significant difference in the level of sCD36 only in the control subjects with the rs3211867 polymorphism; the subjects with the CC genotype had a higher mean level of sCD36 than the subjects with the AA/AC genotype (p = 0.02) (Table 7).

Methylation of Cpg islands of the CD36 promoter

Figure 3 shows the frequencies of the methylation of the CD36 CpG islands in the gene promoter and the DNMT3a level in each group.

CD36 gene methylation was not significantly different between control subjects and subjects with type 2 diabetes, and females with type 2 diabetes did not demonstrate increased levels of CD36 gene methylation (Chi² = 3.56; RR = 1.46; OR = 2.24 [0.96–5.21] 95% CI; p = 0.10). This result was supported by the fact that the DNMT3a level was not significantly different between the control and type 2 diabetes groups (Fig. 3).

Table 8 shows the parameter variations in the study population according to CD36 gene methylation. In the control group, subjects without CD36 gene methylation had a higher triglyceride level than subjects with CD36 gene methylation (p = 0.04).

Figure 4 shows the sCD36 protein and DNMT3a variations in the study population according to CD36 gene methylation and in each group. In each group, subjects...
### Table 5: Baseline population characteristics by genetic variants of the CD36 gene in each group

| Variables               | Control          | Type 2 Diabetes Mellitus | p value |
|-------------------------|------------------|--------------------------|---------|
|                         | GG               | AA/AG        |        | GG               | AA/AG        |        |
| rs1761667               |                  |              |        |                  |              |        |
| Waist size (cm)         | 84.00±10.19      | 83.54±9.20   | 0.87   | 82.32±7.67       | 86.16±7.30   | 0.94   |
| Waist–hip ratio         | 0.82±0.10        | 0.83±0.07    | 0.51   | 0.88±0.07        | 0.89±0.06    | 0.64   |
| Body mass index (kg/m²) | 24.58±2.38       | 23.95±3.07   | 0.42   | 24.30±1.97       | 24.66±2.50   | 0.57   |
| Glycated hemoglobin (%) | 5.08±0.57        | 4.93±0.39    | 0.28   | 9.35±2.16        | 9.29±2.42    | 0.93   |
| IR-HOMA                 | 4.04±1.64        | 3.57±1.70    | 0.34   | 14.04±10.49      | 9.40±4.55    | 0.21   |
| Total cholesterol (g/l) | 2.32±0.42        | 2.04±0.45    | 0.13   | 2.28±0.42        | 2.29±0.58    | 0.93   |
| HDL cholesterol (g/l)   | 0.63±0.13        | 0.61±0.15    | 0.48   | 0.59±0.17        | 0.54±0.18    | 0.38   |
| LDL cholesterol (g/l)   | 1.46±0.30        | 1.34±0.41    | 0.26   | 1.62±0.47        | 1.69±0.59    | 0.63   |
| Triglycerides (g/l)     | 0.84±0.35        | 0.76±0.28    | 0.34   | 0.95±0.63        | 0.92±0.47    | 0.88   |
| CC                      |                  | AA/AC        | p value| CC               | AA/AC        | p value|
| rs3211867               |                  |              |        |                  |              |        |
| Waist size (cm)         | 80.95±9.23       | 85.48±9.54   | 0.10   | 86.90±7.34       | 85.80±7.55   | 0.61   |
| Waist–hip ratio         | 0.80±0.07        | 0.84±0.09    | 0.10   | 0.90±0.08        | 0.87±0.06    | 0.25   |
| Body mass index (kg/m²) | 23.46±2.87       | 24.74±2.60   | 0.12   | 24.46±2.34       | 24.49±2.20   | 0.97   |
| Glycated hemoglobin (%) | 4.86±0.44        | 5.09±0.50    | 0.09   | 9.77±2.53        | 9.02±2.07    | 0.28   |
| IR-HOMA                 | 4.01±1.87        | 3.67±1.57    | 0.51   | 6.41±7.88        | 9.06±5.02    | 0.14   |
| Total cholesterol (g/l) | 2.11±0.48        | 2.15±0.43    | 0.78   | 2.33±0.60        | 2.25±0.42    | 0.65   |
| HDL cholesterol (g/l)   | 0.59±0.15        | 0.64±0.13    | 0.26   | 0.55±0.13        | 0.57±0.20    | 0.61   |
| LDL cholesterol (g/l)   | 1.45±0.37        | 1.37±0.37    | 0.48   | 1.72±0.66        | 1.61±0.43    | 0.49   |
| Triglycerides (g/l)     | 0.73±0.25        | 0.84±0.34    | 0.18   | 1.07±0.68        | 0.85±0.44    | 0.22   |

*HOMA-IR Homeostasis Model Assessment-Insulin Resistance

### Table 6: Comparison of baseline population characteristics between groups by genetic variants at CD36 gene

| Variables               | GG              | p value | AA/AG           | T2DM       | p value |
|-------------------------|-----------------|---------|-----------------|------------|---------|
|                         | Control         | T2DM    |                  |            |         |
| rs1761667               |                  |         |                  |            |         |
| Waist–hip ratio         | 0.82±0.10       | 0.88±0.07 | 0.02*            | 0.83±0.07  | 0.89±0.06 | 0.008** |
| Body mass index (kg/m²) | 24.75±2.61      | 24.30±1.97 | 0.50            | 23.99±3.13 | 24.66±2.50 | 0.40    |
| Total cholesterol (g/l) | 2.23±0.42       | 2.28±0.42 | 0.72            | 2.04±0.45  | 2.29±0.58 | 0.10    |
| HDL cholesterol (g/l)   | 0.63±0.13       | 0.59±0.17 | 0.28            | 0.61±0.15  | 0.54±0.18 | 0.17    |
| LDL cholesterol (g/l)   | 1.46±0.30       | 1.62±0.47 | 0.18            | 1.34±0.41  | 1.69±0.59 | 0.02*   |
| Triglycerides (g/l)     | 0.84±0.35       | 0.95±0.63 | 0.47            | 0.76±0.28  | 0.92±0.48 | 0.13    |
| CC                      |                  |         | AA/AC           |            |         |
| rs3211867               |                  |         |                  |            |         |
| Waist–hip ratio         | 0.80±0.07       | 0.90±0.08 | <0.0001***       | 0.84±0.09  | 0.87±0.06 | 0.11    |
| Body mass index (kg/m²) | 23.46±2.86      | 24.47±2.34 | 0.24            | 24.90±2.80 | 24.49±2.20 | 0.52    |
| Total cholesterol (g/l) | 2.11±0.48       | 2.33±0.60 | 0.22            | 2.15±0.43  | 2.25±0.42 | 0.33    |
| HDL cholesterol (g/l)   | 0.59±0.15       | 0.55±0.13 | 0.39            | 0.64±0.13  | 0.57±0.20 | 0.15    |
| LDL cholesterol (g/l)   | 1.45±0.37       | 1.72±0.66 | 0.11            | 1.37±0.37  | 1.61±0.43 | 0.02*   |
| Triglycerides (g/l)     | 0.73±0.25       | 1.07±0.68 | 0.04*           | 0.84±0.34  | 0.85±0.44 | 0.94    |

*HOMA-IR Homeostasis Model Assessment-Insulin Resistance, T2DM Type 2 Diabetes Mellitus, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.0001
without CD36 gene methylation had a higher sCD36 level than subjects with CD36 gene methylation. This difference in the sCD36 level was statistically significant in the control subjects ($p = 0.03$). Moreover, the DNMT3a level was significantly increased in subjects with CD36 gene methylation compared with subjects without CD36 gene methylation in control subjects ($p = 0.009$) and in subjects with type 2 diabetes ($p = 0.002$).

**Associations between polymorphisms and methylation of the CD36 gene**

Figure 5 shows the interactions between CD36 gene polymorphisms and CD36 gene methylation in each group. In the control group, no association was observed between CD36 gene polymorphisms and CD36 gene methylation. In the type 2 diabetes group, associations between CD36 gene polymorphisms and CD36 gene methylation were noted.

### Table 7: sCD36 level variations according to the different polymorphisms

| SNP CD36 | Control | Type 2 Diabetes Mellitus | p value |
|----------|---------|--------------------------|---------|
| rs1761667 |         |                          |         |
| GG       | 2145.13 ± 536.30 | 3415.64 ± 841.03 | 0.21    |
| AA/AG    | 2943.04 ± 641.38 | 2609.80 ± 851.52 | 0.76    |
| p value  | 0.35    | 0.50                     |         |
| rs3211867 |         |                          |         |
| CC       | 3889.34 ± 776.08 | 3880.58 ± 1081.11 | 0.99    |
| AA/AC    | 1745.31 ± 432.49 | 2434.15 ± 676.63 | 0.40    |
| p value  | 0.02*   | 0.27                     |         |

SNP: Single Nucleotide Polymorphism, sCD36: soluble CD36, *$p \leq 0.05$, **$p \leq 0.01$, ***$p \leq 0.0001$.

### Table 8: Effects of the CD36 gene methylation on clinical and biological parameters

| Variables                        | Control Unmethylated | Control Methylated | p value | Type 2 Diabetes Mellitus Unmethylated | Type 2 Diabetes Mellitus Methylated | p value |
|----------------------------------|----------------------|--------------------|---------|--------------------------------------|------------------------------------|---------|
| Body mass index (kg/m²)          | 24.55 ± 2.84         | 23.81 ± 3.05       | 0.54    | 24.53 ± 2.33                         | 24.41 ± 2.15                       | 0.86    |
| Waist–hip ratio                  | 0.82 ± 0.08          | 0.83 ± 0.10        | 0.87    | 0.88 ± 0.06                          | 0.88 ± 0.07                        | 0.78    |
| Glycated hemoglobin (%)          | 4.89 ± 0.99          | 4.55 ± 1.38        | 0.37    | 9.05 ± 3.00                          | 9.34 ± 2.06                        | 0.96    |
| IR-HOMA                          | 3.81 ± 1.83          | 3.19 ± 1.71        | 0.39    | 12.89 ± 16.78                       | 9.37 ± 5.22                        | 0.31    |
| Total cholesterol (g/l)          | 2.09 ± 0.45          | 2.26 ± 0.41        | 0.20    | 2.37 ± 0.58                         | 2.18 ± 0.35                        | 0.15    |
| HDL cholesterol (g/l)            | 0.61 ± 0.14          | 0.64 ± 0.13        | 0.63    | 0.55 ± 0.13                         | 0.58 ± 0.23                        | 0.52    |
| LDL cholesterol (g/l)            | 1.36 ± 0.37          | 1.52 ± 0.34        | 0.17    | 1.76 ± 0.58                         | 1.52 ± 0.43                        | 0.10    |
| Triglycerides (g/l)              | 0.85 ± 0.32          | 0.66 ± 0.25        | 0.04*   | 0.89 ± 0.49                         | 1.00 ± 0.63                        | 0.51    |

HOMA-IR: Homeostasis Model Assessment-Insulin Resistance, *$p \leq 0.05$, **$p \leq 0.01$, ***$p \leq 0.0001$.
**Fig. 4** CD36 gene methylation and its influence on the sCD36 protein level and DNMT3a enzyme level. In Panels A and C, a symbol without a filling is unmethylated, and a symbol with a single filling is methylated. In Panels B and D, a symbol without a filling is the control group, and a symbol with a single filling is the type 2 diabetes group. A p value ≤ 5% was considered significant.

**Fig. 5** Associations between CD36 gene polymorphisms and CD36 gene methylation. The symbol without filling is unmethylated, and the symbol with a single filling is methylated. A p value ≤ 5% was considered significant.
We found that the AA/AG genotype of rs1761667 was significantly associated with \( CD36 \) gene methylation (\( RR = 2.14; \) OR = 5.35 [1.59–17.96] 95% CI; \( p < 0.01 \)), and the CC genotype of rs3211867 was significantly associated with \( CD36 \) gene methylation (\( RR = 2.68; \) OR = 12.75 [2.29–70.97] 95% CI; \( p < 0.01 \)) (Fig. 5).

**Combined effects of \( CD36 \) gene polymorphisms and methylation on the sCD36 level**

In each group, the combined effects of the polymorphisms and methylation of the \( CD36 \) gene on sCD36 levels were not statistically significant, as shown in Table 9.

**Discussion**

The presence of diabetes can increase a woman’s risk of heart disease twofold. In addition, the presence of diabetes overshadows the protective effects of the premenopausal state [18]. The establishment of markers of insulin resistance and the development of type 2 diabetes has been a challenge and determining point in this field of research. The plasma sCD36 level has been suggested as an adjunct marker for diabetes mellitus [19]. Previous studies have indicated that sCD36 is strongly correlated with insulin resistance and the development of type 2 diabetes [7, 8, 10, 11].

In our present study, the sCD36 level was not significantly different between the control and type 2 diabetes groups (516.72 and 636.95, respectively, \( p = 0.24 \)). The increase in the sCD36 level in the control group was accompanied by a significant decrease in the HDL-cholesterol levels (\( r = −0.52 \); \( p = 0.0001 \)) and the triglycerides levels (\( r = −0.36 \); \( p = 0.01 \)). However, in the type 2 diabetes group, an increase in sCD36 levels was associated with a significant increase in total cholesterol levels (\( r = 0.28 \); \( p = 0.04 \)).

\( CD36 \) gene polymorphisms were not a risk factor for type 2 diabetes (for rs1761667, OR = 0.79 [0.43–1.44] \( p = 0.9 \); for rs3211867, OR = 1 [0.56–1.79] \( p = 0.9 \)). A link has been demonstrated between the sCD36 level and the SNP rs3211867. In the control group, subjects harboring the AA/AC genotype had lower plasma sCD36 levels than subjects harboring the CC genotype (\( p = 0.02 \)). This difference in sCD36 levels according to the genotypes of rs3211867 (genotype CC vs AA/AC) was not significant in the group with type 2 diabetes. In addition, we found an increase in sCD36 levels in the subjects with type 2 diabetes harboring the AA/AC genotype compared to the control subjects harboring the AA/AC genotype.

The results show that in the control group, subjects without \( CD36 \) gene methylation had higher plasma sCD36 levels than subjects with \( CD36 \) gene methylation (\( p = 0.03 \)). This difference in sCD36 levels according to \( CD36 \) gene methylation was not significant in the group with type 2 diabetes. In addition, we found a nonsignificant increase in sCD36 levels in the type 2 diabetes group with \( CD36 \) gene methylation compared to the control group with \( CD36 \) gene methylation (\( p = 0.26 \)).

In the type 2 diabetes group, subjects harboring the AA/AG genotype of rs1761667 were fivefold more likely to have \( CD36 \) gene methylation than subjects harboring the GG genotype (\( OR = 5.35 [1.59–17.96] \); \( p < 0.01 \)). However, for rs3211867, in the type 2 diabetes group, subjects harboring the CC genotype were 13-fold more likely to have \( CD36 \) gene methylation than subjects harboring the AA/AC genotype (\( OR = 12.75 [2.29–70.97] \); \( p < 0.01 \)).

The combination of \( CD36 \) gene polymorphisms with \( CD36 \) gene methylation had no impact on the plasma sCD36 level in the control group or the diabetes group.

The allelic frequencies and genotype distribution of the different \( CD36 \) SNPs (rs1761667 and rs3211867) were not significantly different regardless of the considered group (control or diabetes group). However, previous studies in other populations have shown that \( CD36 \) SNPs are strongly associated with obesity [20–22], which is a major risk factor for type 2 diabetes [23]. The difference

| Table 9 | Impacts of the combined effects of the \( CD36 \) gene polymorphisms and methylation on the sCD36 level |
|---------|-------------------------------------------------|
| Variables | Control | | Type 2 Diabetes Mellitus |
| | Unmethylated | Methylated | \( p \) value | Unmethylated | Methylated | \( p \) value |
| rs1761667 | | | | | | |
| GG | 1609.31 ± 620.30 | 3216.75 ± 969.51 | 0.19 | 2891.94 ± 930.93 | 4528.50 ± 1763.06 | 0.43 |
| AA/AG | 3340.55 ± 748.39 | 1273.50 ± 862.93 | 0.09 | 1527.27 ± 760.96 | 3617.50 ± 1364.87 | 0.16 |
| \( p \) value | 0.08 | 0.16 | | 0.21 | 0.69 | |
| rs3211867 | | | | | | |
| CC | 3661.26 ± 846.70 | 5828.00 ± 1137.50 | 0.23 | 2375.06 ± 1167.51 | 4884.25 ± 1599.21 | 0.22 |
| AA/AC | 1682.95 ± 570.87 | 1858.68 ± 673.51 | 0.84 | 2238.13 ± 793.66 | 2826.20 ± 1319.28 | 0.71 |
| \( p \) value | 0.06 | 0.11 | | 0.92 | 0.33 | |
between the results obtained here and those of the former studies is most likely due to racial-ethnic discrepancies and several other differences, such as sample size. However, in the control group, subjects with the CC genotype had significantly higher sCD36 levels than those with the AA/AC genotype ($p = 0.003$). These results are in line with those of other authors who have reported other CD36 SNPs and found that the AA genotype and A allele were characterized by a lower level of CD36 protein expression [22, 24] and a consequent decrease in sCD36 levels. These diminishing effects of the CD36 polymorphism on sCD36 levels would be compensated for in subjects with type 2 diabetes mellitus. Furthermore, the results showed that in both groups, subjects without CD36 gene methylation had higher sCD36 levels than subjects with CD36 gene methylation, and this difference was statistically significant in the control group ($p = 0.003$). This finding corroborates the literature data because DNA methylation has been associated with stable alterations of gene expression and implicated in reducing the circulating level of this protein [25]. However, this condition was not verified in the type 2 diabetes group in this study. The subjects with type 2 diabetes with CD36 gene methylation had an increase in sCD36 levels and a consequent absence of a significant difference in sCD36 levels compared to subjects with type 2 diabetes without CD36 gene methylation.

Previous studies have indicated that sCD36 is strongly and positively correlated with insulin resistance and the development of type 2 diabetes [8, 10, 11].

Our results support a potential interaction between genetic variations and DNA methylation in type 2 diabetes. The mechanism linked to this observation remains to be clarified.

We did not observe any particular effect of the combination of CD36 gene polymorphisms and methylation on the circulating sCD36 level in the control group or the type 2 diabetes group.

Subjects with CD36 gene methylation had a significant increase in the DNMT3a level in the control group ($p = 0.009$) and in the type 2 diabetes group ($p = 0.002$). We believe that it is quite normal for the DNMT3a level to be higher in subjects with CD36 methylation. DNA methylation is performed by enzymes from the DNA methyltransferase (DNMT) gene family, the role of which is to affix a methyl group to the DNA cytosines. The DNMT3a enzyme is part of the DNA methyltransferase (DNMT) gene family. It preferentially targets unmethylated DNA and provides de novo methylations [26]. DNMT3a is the enzyme responsible for attaching methyl groups to DNA during replication and de novo methylation [27]. DNMT3a was significantly increased in subjects with CD36 gene methylation, which further supports their observed methyl status.

sCD36 is involved in macrophage cholesterol and phospholipid transport, and an increase in sCD36 levels reduces circulating plasma cholesterol levels. Studies have already reported an increase in circulating cholesterol by partial or complete CD36 deficiency [28]. However, we noted an increase in circulating cholesterol levels in subjects with type 2 diabetes despite the increase in the circulating level of sCD36. It would be interesting to elucidate these findings. The CD36 protein has several functions related to fatty acid regulation, such as the transmembrane transportation of LDL [29]. Signal transduction triggered by CD36 ligand binding involves proteins in cellular pathways relevant to some of the metabolic complications of obesity, such as insulin resistance, type 2 diabetes, inflammation status, atherosclerosis, and thrombosis, as previously reviewed [30].

Our study had specific limitations resulting from the use of a small and exclusively female study population. For this, we intend to continue the study on a larger cohort, including males and females, to better establish these results.

**Conclusion**

In this study of Senegalese females, the sCD36 level was increased in subjects with type 2 diabetes. sCD36 levels were decreased in subjects with CD36 gene methylation and in subjects with CD36 gene polymorphisms (rs3211867). However, these diminishing effects were compensated by the increase in sCD36 levels in subjects with type 2 diabetes. Thus, even a combination of the effects of CD36 polymorphisms and CD36 methylation did not significantly reduce sCD36 levels in subjects with type 2 diabetes. We intend to continue the study on a larger cohort to better establish the results.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12920-022-01337-2.

---

**Additional file 1.** Sample of the data collection sheet on diabetes subjects.

**Additional file 2.** Sample of the data collection sheet on control subjects.

**Additional file 3.** Corresponds to the gels allowing the determination of the methylated profile or not of the CD36 gene.

**Additional file 4.** Correspond to ELISA plates.

**Additional file 5.** Correspond to ELISA plates.

**Additional file 6.** Correspond to ELISA plates.

---

**Acknowledgements**

URLs189 (Environment, Health, Societies), CNRS, CNRST, Bamako-UCAD, Dakar, Senegal.
Author contributions
MT: main author, conducted participant survey, clinical examination, collection of blood samples, laboratory experiments, and article writing. AS: supervisor, participated in the research project study, and supervision of works. MS: collected blood samples. ST: determined the dosage of biochemical parameters. CABM: collected blood samples and acted as the cold storage manager. AKS: performed daily transport of blood samples to the cold room. AB-D: performed daily transport of blood samples to the cold room. AB: participated in the research project study. MOK: participated in the research project study. MS: participated in the research project study. LG: participated in the research project study and supervision of works. All authors read and approved the final manuscript.

Funding
Campus France.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. Corresponding author email: drmaimounatoure@gmail.com. The ClinVar accession numbers for the submission are: SCV002552557 to NC_000007.14:g.80657624C > A/HP:0,005,978.

Declarations
Ethical approval and consent to participate
This study protocol was carried out according to the Declaration of Helsinki (1989) of the World Medical Association and was approved by our institutional ethics committee of UCAD (Protocole 027512018/CECrUCA). Written consent was obtained from all the participants for this study and its ethics committee of UCAD (Protocole 027512018/CERruCAD). Informed consent was written obtained from all the participants for this study and its publication.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Laboratoire de Physiologie Humaine et d’Explorations Fonctionnelles, Faculté de Médecine, de Pharmacie et d’Odontostomatologie (FMPOS), de l’Université Cheikh Anta Diop (UCAD), Dakar, Sénégal. 2 Laboratoire de Physiologie Pharmaceutique, Faculté de Médecine, de Pharmacie et d’Odontostomatologie (FMPOS), de l’Université Cheikh Anta Diop (UCAD), Dakar, Sénégal. 3 Laboratoire de Biochimie et de Biologie Moléculaire, Faculté de Médecine, de Pharmacie et d’Odontostomatologie (FMPOS), de l’Université Cheikh Anta Diop (UCAD), Dakar, Sénégal. 4 Laboratoire de Biochimie et Biologie Moléculaire, Faculté de Médecine, de Pharmacie et d’Odontostomatologie (FMPOS), de l’Université Cheikh Anta Diop (UCAD), Dakar, Sénégal. 5 URL3189 ESS Environnement, Santé, Sociétés, CNRS, CNRST, Bamoko-UCAD, Dakar, Sénégal.

Received: 10 October 2021 Accepted: 12 August 2022
Published online: 29 August 2022

References
1. International Diabetes Federation. IDF Atlas, 6thed. Brussels, Belgium: International Diabetes Federation, 2019.
2. Thorne RF, Ihaadat NM, Rafton JK, Burns GF. CD36 is a receptor for oxidized high-density lipoprotein: implications for the development of atherosclerosis. FEBS Lett. 2007;581:1227–32. https://doi.org/10.1016/j.febslet.2007.02.043.
3. Febbaio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Investig. 2001;108:785–91. https://doi.org/10.1172/JCI14006.
4. Susztak K, Ciccone E, McCue P, Sharma K, Bottinger EP. Multiple metabolic hits converge on CD36 as a novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoS Med. 2005;2(2): e45. https://doi.org/10.1371/journal.pmed.0020045.
5. Corpeleijn E, Van der Kallen CJH, Kruisjhoop M, Magagnin MGP, de Bruin TWA, Feskens EJM, et al. Direct association of a promoter polymorphism in the CD36/FAT fatty acid transporter gene with type 2 diabetes mellitus and insulin resistance. Diabet Med. 2006;23:907–11. https://doi.org/10.1111/j.1464-5491.2006.01888.x.
6. LépBre F, Linton KJ, Lacquemant C, Vatin V, Samson C, Dina C, et al. Genetic study of the CD36 gene in a French diabetic population. Diabet Metab. 2004;30:459–63.
7. Handberg A, Levin K, Hoglund K, Beck-Nielsen H. Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance. Circulation. 2006;114:1169–76. https://doi.org/10.1161/CIRCULATIONAHA.106.626135.
8. Handberg A, Hoglund K, Gastaldelli A, Flyvbjerg A, Dekker JM, Petrie J, et al. Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance, and fatty liver in a nondiabetic healthy population. J Intern Med. 2012;271:294–304. https://doi.org/10.1111/j.1365-2796.2011.02442.x.
9. Koonen DP, Jensen MK, Handberg A. Soluble CD36—A marker of the (pathophysiological) role of CD36 in the metabolic syndrome? Arch Physiol Biochem. 2011;117:57–63. https://doi.org/10.3109/13813455.2010.543136.
10. Glimtberg D, Hjoulund K, Andersen M, Henriksen JE, Beck Nielsen H, Handberg A. Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diabetes Care. 2008;31:328–34.
11. Handberg A, Norberg M, Stenlund H, Hallmans G, Attermann J, Eriksson JW. Soluble CD36 (sCD36) clusters with markers of insulin resistance and high sCD36 are associated with increased type 2 diabetes risk. J Clin Endocrinol Metab. 2010;95:1399–46. https://doi.org/10.1210/jc.2009-0202.
12. Pepino MY, Love-Gregory L, Klein S, Abumrad NA. The fatty acid translocase gene CD36 and lingual lipase influence oral sensitivity to fat in obese subjects. J Lipid Res. 2012;53:561–6. https://doi.org/10.1194/jlr.M21873.
13. Keller RL, Liang LC, Sakimura J, May D, van Belle C, Breen C, et al. Common variants in the CD36 gene are associated with oral fat perception, fat preferences, and obesity in African Americans. Obesity (Silver Spring). 2012;20:1066–73. https://doi.org/10.1038/oby.2011.374.
14. Love-Gregory L, Sherva R, Sun L, Wasson J, Schappe T, Doria A, et al. Variants in the CD36 gene associate with the metabolic syndrome and high-density lipoprotein cholesterol. Hum Mol Genet. 2008;17:1695–704. https://doi.org/10.1093/hmg/ddn060.
15. Friedewald WT, Levy RJ, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502. PMID: 4337382.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1984;28:412–9. https://doi.org/10.1007/BF02880883.
17. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002;18:427–31. https://doi.org/10.1093/bioinformatics/18.11.427.
18. Barnes AS. The epidemic of obesity and diabetes. Trends and treatments. Cardiovasc Diabetol Women 2011;38(2):142–144.
19. Shiju TM, Mohan V, Balasubramaniam M, Viswanathan P, Soluble CD36 in plasma and urine: a plausible prognostic marker for diabetic nephropathy. J Diabetes Complicat. 2015;29:400–6. https://doi.org/10.1016/j.jdiacomp.2014.12.012.
20. Bokor S, Legry V, Meirhaeghe A, Ruiz JR, Mauro B, Widhalm K, et al. Single-nucleotide polymorphism of CD36 locus and obesity in European adolescents. Obesity. 2010;18:1398–403. https://doi.org/10.1038/oby.2009.412.
21. Melis M, Carta G, Mintus S, Pintus P, Pras CA, Murr e E, et al. Polymorphism rs1761667 in the CD36 gene is associated with changes in fatty acid metabolism and circulating endocannabinoid levels distinctively in normal weight and obese subjects. Front Physiol. 2017;8:1006. https://doi.org/10.3389/fphys.2017.01006.
22. Love-Gregory L, Sherva R, Schappe T, Qi JS, McCrea J, Klein S, et al. Common CD36 SNPs reduce protein expression and may contribute to a
protective atherogenic profile. Hum Mol Genet. 2011;20:193–201. https://doi.org/10.1093/hmg/ddq449.

23. Momeni-Moghaddam MA, Asadikaram G, Akbari H, Abolhassani M, Masoumi M, Nadimy Z, Khaksari Mohammad. CD36 gene polymorphism rs1761667 (G>A) is associated with hypertension and coronary artery disease in an Iranian population. Cardiovasc Disorders 2019;19:140, 3–9. https://doi.org/10.1186/s12872-019-1111-6.

24. Ghosh A, Murugesan G, Chen K, Zhang L, Wang Q, Febbraio M, et al. Platelet CD36 surface expression levels affect functional responses to oxidized LDL and are associated with inheritance of specific genetic polymorphisms. Blood. 2011;117:6355–66. https://doi.org/10.1182/blood-2011-02-338582.

25. Reddy MA, Zhang E, Natarajan R. Epigenetic mechanisms in diabetic complications and metabolic memory. Diabetologia. 2015;58:443–55. https://doi.org/10.1007/s00125-014-3462-y.

26. Tajima S, Suetake I, Takeshita K, Nakagawa A, Kimura H. Domain structure of the Dnmt1, Dnmt3a, and Dnmt3b DNA methyltransferases. Adv Exp Med Biol. 2016;945:63–86. https://doi.org/10.1007/978-1-4939-6085-4.

27. Ling C, Rönn T. Epigenetics in human obesity and type 2 diabetes. Cell Metab. 2019;29(5):1028–44. https://doi.org/10.1016/j.cmet.2019.03.009.

28. Masuda D, Hirano K, Oku H, et al. Chylomicron remnants are increased in the postprandial state in CD36 deficiency. J Lipid Res. 2009;50:999–1011. https://doi.org/10.1194/jlr.P070032-JLR200.

29. Van de Langenberg D, Vlaanderen JJ, Dolle MET, Handberg A, Vermeulen RCH, van Kerkhof LWM. Plasma sCD36 as non-circadian marker of chronic circadian disturbance in shift workers. PLoS ONE. 2019;14(10): e0223522. https://doi.org/10.1371/journal.pone.0223522.

30. Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal. 2009, 26, 2(72):re3. https://doi.org/10.1126/scisignal.272re3

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.